The novel squamosamide derivative FLZ protects against 6-hydroxydopamine-induced apoptosis through inhibition of related signal transduction in SH-SY5Y cells

European Journal of Pharmacology

Volumn 561, Issue 1-3, 2007, Pages 1-6

  Zhang, Dan ^a   Zhang, Jian Jun ^a   Liu, Geng Tao ^a  

^a INSTITUTE OF MATERIA MEDICA   (China)

Author keywords

6 OHDA; Apoptosis; Caspase 3; FLZ; Parkinson's disease

Indexed keywords

ACRYLAMIDE DERIVATIVE; APOPTOSIS INDUCING FACTOR; CASPASE 3; CYTOCHROME C; HERBACEOUS AGENT; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; N [2 (4 HYDROXYPHENYL)ETHYL] 2 (2,5 DIMETHOXYPHENYL) 3 (3 METHOXY 4 HYDROXYPHENYL)ACRYLAMIDE; OXIDOPAMINE; SQUAMOSAMIDE DERIVATIVE; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CELL CULTURE; CELL LINE; CONCENTRATION RESPONSE; CULTURE MEDIUM; DRUG EFFECT; DRUG MECHANISM; DRUG STRUCTURE; ENZYME RELEASE; HUMAN; HUMAN CELL; NEUROPROTECTION; PRIORITY JOURNAL; PROTEIN SECRETION; SIGNAL TRANSDUCTION;

APOPTOSIS; APOPTOSIS INDUCING FACTOR; BENZENEACETAMIDES; CASPASE 3; CELL LINE; CELL SURVIVAL; CYTOCHROMES C; DRUG DELIVERY SYSTEMS; MODELS, BIOLOGICAL; NEUROPROTECTIVE AGENTS; NF-KAPPA B; OXIDOPAMINE; PARKINSON DISEASE; PHENOLS; SIGNAL TRANSDUCTION;

EID: 33947208478     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2006.11.015     Document Type: Article

References (24)

1. Abu-Qare A.W., and Abou-Donia M.B. Biomarkers of apoptosis: release of cytochrome c, activation of caspase-3, induction of 8-hydroxy-2′-deoxyguanosine, increased 3-nitrotyrosine, and alteration of p53 gene. J. Toxicol. Environ. Health 4 (2001) 313-332
2. Amoroso S., Gioielli A., Cataldi M., Di Renzo G., and Annunziato L. In the neuronal cell line SH-SY5Y, oxidative stress-induced free radical overproduction causes cell death without any participation of intracellular Ca (2+) increase. Biochim. Biophys. Acta 1452 (1999) 151-160
3. Andrew R., Watson D.G., Best S.A., Midgley J.M., Wenlong H., and Petty R.K. The determination of hydroxydopamines and other trace amines in the urine of parkinsonian patients and normal controls. Neurochem. Res. 18 (1993) 1175-1177
4. Blum D., Torch S., Lambeng N., Nissou M., Benabid A.L., Sadoul R., and Verna J.M. Molecular pathways involved in the neurotoxicity of 6-OHDA, dopamine and MPTP: contribution to the apoptotic theory in Parkinson's disease. Prog. Neurobiol. 65 (2001) 135-172
5. Darzynkiewicz Z., Bruno S., Del Bino G., Gorczyca W., Hotz M.A., Lassota P., and Traganos F. Features of apoptotic cells measured by flow cytometry. Cytometry 13 (1992) 795-808
6. Feng W., Wei H., and Liu G.T. Pharmacological study of the novel compound FLZ against experimental Parkinson's models and its active mechanism. Mol. Neurobiol. 31 (2005) 295-300
7. Gorman A.M., Orrenius S., and Ceccateli S. Apoptosis in neuronal cells: role of caspases. NeuroReport 9 (1998) 49-55
8. Guerrini L., Blasi F., and Denis-Donini S. Synaptic activation of Nfkappa B by glutamate in cerebellar granule neurons in vitro. Proc. Natl. Acad. Sci. U. S. A. 92 (1995) 9077-9081
9. Hartmann A., Hunot S., Michel P.P., Muriel M.P., Vyas S., Faucheux B.A., Mouatt-Prigent A., Turmel H., Srinivasan A., Ruberg M., Evan G.I., Agid Y., and Hirsch E.C. Caspase-3: a vulnerability factor and final effector in apoptotic death of dopaminergic neurons in Parkinson's disease. Proc. Natl. Acad. Sci. U. S. A. 97 (2000) 2875-2880
10. He Y., Lee T., and Leong S.K. 6-Hydroxydopamine induced apoptosis of dopaminergic cells in the rat substantia nigra. Brain Res. 858 (2000) 163-166
11. Hong S.J., Dawson T.M., and Dawson V.L. Nuclear and mitochondrial conversations in cell death: PARP-1 and AIF signaling. Trends Pharmacol. Sci. 25 (2004) 259-264
12. Hunot S., Brugg B., Ricard D., Michel P.P., Muriel M.P., Ruberg M., Faucheux B.A., Agid Y., and Hirsch E.C. Nuclear translocation of NF-kappaB is increased in dopaminergic neurons of patients with Parkinson disease. Proc. Natl. Acad. Sci. U. S. A. 94 (1997) 7531-7536
13. Jellinger K.A. Cell death mechanisms in Parkinson's disease. J. Neural Transm. 107 (2000) 1-29
14. Lenardo M.J., and Baltimore D. NF-kappa B: a pleiotropic mediator of inducible and tissue-specific gene control. Cell 58 (1989) 227-229
15. Newhouse K., Hsuan S.L., Chang S.H., Cai B., Wang Y., and Xia Z. Rotenone-induced apoptosis is mediated by p38 And JNK MAP kinases in human dopaminergic SH-SY5Y cells. Toxicol. Sci. 79 (2004) 137-146
16. Pahl H.L., and Baeuerle P.A. The ER-overload response: activation of NF-kappa B. Trends Biochem. Sci. 22 (1997) 63-67
17. Pahl H.L., Sester M., Burgert H.G., and Baeuerle P.A. Activation of transcription factor NF-kappaB by the adenovirus E3/19K protein requires its ER retention. J. Cell Biol. 132 (1996) 511-522
18. Porter A.G., and Janicke R.U. Emerging roles of caspase-3 in apoptosis. Cell Death Differ. 6 (1999) 99-104
19. Schapira A.H., Gu M., Taanman J.W., Tabrizi S.J., Seaton T., Cleeter M., and Cooper J.M. Mitochondria in the etiology and pathogenesis of Parkinson's disease. Ann. Neurol. 44 (1998) 89-98
20. Schober A. Classic toxin-induced animal models of Parkinson's disease: 6-OHDA and MPTP. Cell Tissue Res. 318 (2004) 215-224
21. Storch A., Kaftan A., Burkhardt K., and Schwarz J. 1-Methyl-6, 7-dihydroxy-1, 2, 3, 4-tetrahydroisoquinoline salsolinol is toxic to dopaminergic neuroblastoma SH-SY5Y cells via impairment of cellular energy metabolism. Brain Res. 855 (2000) 67-75
22. Tirmenstein M.A., Hu C.X., Scicchitano M.S., Narayanan P.K., McFarland D.C., Thomas H.C., and Schwartz L.W. Effects of 6-hydroxydopamine on mitochondrial function and glutathione status in SH-SY5Y human neuroblastoma cells. Toxicol. In Vitro 19 (2005) 471-479
23. von Coelln R., Kugler S., Bahr M., Weller M., Dichgans J., and Schulz J.B. Rescue from death but not from functional impairment: caspase inhibition protects dopaminergic cells against 6-hydroxydopamine-induced apoptosis but not against the loss of their terminals. J. Neurochem. 77 (2001) 263-273
24. Waldmeier P.C., and Tatton W.G. Interrupting apoptosis in neurodegenerative disease: potential for effective therapy?. Drug Discov. Today 9 (2004) 210-218